Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899738 | 0.77 | IDO1 (0.53) | IDO1GSK3BALDH1A1BRPF1CREBBP | |
| SCHEMBL11462474 | 0.76 | IDO1 (0.52) | IDO1GSK3BALDH1A1BRPF1CREBBP | |
| SCHEMBL19985146 | 0.75 | IDO1 (0.47) | IDO1GSK3BALDH1A1BRPF1CREBBP | |
| SCHEMBL22907690 | 0.75 | IDO1 (0.47) | IDO1GSK3BALDH1A1BRPF1CREBBP | |
| SCHEMBL5144419 | 0.74 | IDO1 (0.50) | IDO1GSK3BALDH1A1BRPF1CREBBP | |
| SCHEMBL19410659 | 0.74 | IDO1 (0.50) | IDO1GSK3BALDH1A1BRPF1CREBBP | |
| SCHEMBL20600322 | 0.74 | IDO1 (0.50) | IDO1GSK3BALDH1A1BRPF1CREBBP | |
| SCHEMBL260994 | 0.74 | BRPF1 (0.53) | IDO1GSK3BALDH1A1BRPF1CREBBP | |
| SCHEMBL87439 | 0.74 | IDO1 (0.50) | IDO1GSK3BALDH1A1BRPF1CREBBP | |
| SCHEMBL1462143 | 0.74 | IDO1 (0.55) | IDO1GSK3BALDH1A1BRPF1CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261587-A1 | POLYMER-SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS (US) | 2020-08-20 | — | — | US | disclosed |
| US-10682418-B2 | Polymer-sunitinib conjugates | NEKTAR THERAPEUTICS (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180043028-A1 | POLYMER-SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS | 2018-02-15 | — | — | US | disclosed |
| US-9827326-B2 | Polymer-sunitinib conjugates | NEKTAR THERAPEUTICS (US) | 2017-11-28 | — | — | US | disclosed |
| EP-2654799-B1 | POLYMER-SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20130331425-A1 | POLYMER-SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS (US) | 2013-12-12 | — | — | US | disclosed |
| EP-2654799-A1 | POLYMER-SUNITINIB CONJUGATES | Nektar Therapeutics (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012088529-A1 | POLYMER-SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-06-28 | — | — | WO | disclosed |
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| JP-2008133274-A | AZULENE COMPOUND | IND TECHNOL RES INST | 2008-06-12 | — | — | JP | disclosed |
| EP-1074542-B1 | SULFONAMIDE-CONTAINING INDOLE COMPOUNDS | EISAI CO LTD (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| US-6673787-B2 | PYRIMIDINESULFONAMIDE CONTAINING INDOLE COMPOUNDS USED AS ANTIANGIOGENIC AND ANTITUMOR AGENTS | EISAI CO., LTD. (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| US-6469043-B1 | ANTIANGIOGENIC AGENT WITH ANTITUMOR, ANTIMETASTATIC PROPERTIES WHICH SHOWS HIGH SAFETY | EISAI CO., LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| US-20020128483-A1 | Sulfonamide-containing indole compounds | EISAI CO., LTD. | 2002-09-12 | — | — | US | disclosed |
| US-20020128480-A1 | Sulfonamide-containing indole compounds | EISAI CO., LTD. | 2002-09-12 | — | — | US | disclosed |
| EP-1074542-A1 | SULFONAMIDE-CONTAINING INDOLE COMPOUNDS | Eisai Co., Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | IDO1 4585/4885GSK3B 597/4885ALDH1A1 1256/4885 |
| US-20200261587-A1 | POLYMER-SUNITINIB CONJUGATES | FLT4, TEK, TIE1 | IDO1 2090/4885GSK3B 1035/4885ALDH1A1 3150/4885 |
| US-20130331425-A1 | POLYMER-SUNITINIB CONJUGATES | FLT4, TEK, TIE1 | IDO1 2090/4885GSK3B 1035/4885ALDH1A1 3150/4885 |
| US-20020128480-A1 | Sulfonamide-containing indole compounds | IDO1, HCCS, VEGFA | IDO1 1/4885GSK3B 2177/4885ALDH1A1 417/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | IDO1 4585/4885GSK3B 597/4885ALDH1A1 1256/4885 |
| US-20020128483-A1 | Sulfonamide-containing indole compounds | IDO1, HCCS, VEGFA | IDO1 1/4885GSK3B 2227/4885ALDH1A1 422/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | IDO1 4659/4885GSK3B 502/4885ALDH1A1 1266/4885 |
| US-20180043028-A1 | POLYMER-SUNITINIB CONJUGATES | FLT4, TEK, TIE1 | IDO1 2090/4885GSK3B 1035/4885ALDH1A1 3150/4885 |
| US-10682418-B2 | Polymer-sunitinib conjugates | FLT4, TEK, TIE1 | IDO1 2090/4885GSK3B 1035/4885ALDH1A1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.